GORE® PROPATEN® Vascular Graft, a leading prosthetic vascular graft for lower extremity revascularization, is specifically designed to reduce the risk of acute graft thrombotic failure. With more than a decade of strong performance that includes improving outcomes and reducing reinterventions, this longstanding bypass graft helps deliver both proven clinical and economic value for patients and hospitals.

Strength of leadership

600K+ Devices implanted | 2,000+ Limbs studied

With more than 10 years of performance, over 600,000 devices implanted, and over 2,000 limbs studied, the GORE® PROPATEN® Vascular Graft is a leading prosthetic bypass graft solution for proven clinical performance and low cumulative cost of care.


GORE® PROPATEN® Vascular Graft

Above-knee bypass primary patency
Above-knee bypass primary patency

Above-knee data

Below-knee bypass primary patency
Below-knee bypass primary patency

Below-knee data

* Overall weighted average primary patency is based on data from 15 peer-reviewed publications meeting pre-determined inclusion criteria.


Proven patency

By substantially reducing acute graft thrombosis within hours after implantation, the CBAS Heparin Surface on the GORE® PROPATEN® Vascular Graft provides clinical benefits that standard ePTFE grafts do not.1


Fewer occlusions
50% reduction in risk of graft occlusion compared to standard ePTFE in critical limb ischemia (CLI) patients.2


Improved patient outcomes
Higher primary and secondary patency, and higher limb salvage for below-knee bypass compared to standard ePTFE from 1–3 years.3

Improved clinical outcomes

* Weighted average of GORE® PROPATEN® Vascular Graft data.

** Weighted average of standard ePTFE data.


Measurable value

The GORE® PROPATEN® Vascular Graft is a leading prosthetic bypass graft solution for proven clinical performance and low cumulative cost of care.


 

Low treatment cost

GORE® PROPATEN® Vascular Graft: long-term value

28% Patients

Improvement in amputation-free survival

36% Physicians

Decrease in revision procedures

38% Providers

Decrease in average costs

† Based on the 3-year published clinical performance and economic model.


Lasting thromboresistance. Proven technology.7

CBAS Heparin Surface

The CBAS Heparin Surface of the GORE® PROPATEN® Vascular Graft consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin’s anticoagulant activity.


Proven

Heparin availability

Performance-ready heparin active site.4, 6


Proven

Heparin bioactivity

Unmatched, persistent ability to take up antithrombin.1, 5


Proven

Lasting thromboresistance

Improved surface hemocompatibility resulting from heparin availability and bioactivity.1, 4–7




Sustained heparin bioactivity8

In vivo canine carotid artery interposition model

The CBAS Heparin Surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft (top) remains free of thrombus, while the 3 mm diameter control ePTFE graft (bottom) is covered with thrombus in an acute two-hour in vivo canine carotid artery interposition model.

Learn more about CBAS

  1. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437.
  2. Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian PROPATEN® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomized clinical controlled multi-centre trial. European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.
  3. GORE® PROPATEN® Vascular Graft. W. L. Gore & Associates Web site. https://www.goremedical.com/propaten/references. Accessed May 15, 2019.
  4. Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J. Heparin surfaces: impact of immobilization chemistry on hemocompatibility and protein adsorption. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2014;102(8):1817-1824.
  5. Freeman J, Chen A, Weinberg RJ, Okada T, Chen C, Lin PH. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded PTFE Propaten Graft in a chronic canine femoral artery bypass model. Annals of Vascular Surgery 2018;49:295-303.
  6. Biran R, Pond D. Heparin coatings for improving blood compatibility of medical devices. Advanced Drug Delivery Reviews 2017;112:12-23.
  7. CBAS Heparin Surface. W. L. Gore & Associates Web site. https://www.goremedical.com/cbas/references. Accessed May 3, 2019.
  8. Biran R. Heparin Activity and Concentration Values from 52 and 96 Month Duration Clinical Explants of the GORE® PROPATEN® Vascular Graft. Flagstaff, AZ: W.L. Gore & Associates, Inc; 2011 [Work plan]. WP104647

GORE PROPATEN Vascular Graft